Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and/or Mast Cell Disorders (BIRD-A)

This study aims to build up a clinico-biological bank of samples from patients suspected of or suffering from allergic diseases (including asthma) or mast cell diseases in order to support future research in the field of allergic diseases. The biobank will help to identify new prognostic, diagnostic and/or predictive biomarkers.

Study Overview

• Status: Recruiting
• Conditions: Asthma; Allergic Diseases; Mast Cell Disorders

Detailed Description

This is a prospective monocentric collection of biological samples combined with clinical and paraclinical data from patients suffering from allergic diseases, asthma or mast cell disorders. The aim of this collection is to collect biological samples and clinical data to be used for various exploratory, diagnostic and/or prospective and/or predictive studies.

The samples and data will be pseudonymised, i.e. identified by the first letter of the patient's surname and first name and by a number allocated in chronological order of patient inclusion, and will be stored in a bank. The samples and data making up this clinico-biological bank will be used for subsequent exploratory work used as a priority to answer questions from the Toulouse University Hospital teams in the field of allergic diseases, asthma and/or mast cell disorders, in accordance with the information given to the patient. They may also be transferred to specialised research teams as part of national or international collaborations, or sold to academic or industrial partners. These transfers as part of collaborations or assignments will be legally governed by contracts guaranteeing compliance with the RGPD, where applicable, and the use of these samples in accordance with current legislation and the information provided to patients.

• Study Type: Observational
• Enrollment (Estimated): 3200

Contacts and Locations

• Study Contact: Name: Laurent GUILLEMINAULT, MD; Phone Number: 05 67 77 17 51; Email: guilleminault.l@chu-toulouse.fr

Study Locations

• France
  • Toulouse, France, 31059
    • Recruiting
    • Laurent GUILLEMINAULT
    • Contact: Laurent GUILLEMINAULT, MD; Phone Number: 05 67 77 17 51; Email: guilleminault@chu-toulouse.fr
    • Sub-Investigator: Cristina LIVIDEANU, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

patients with respiratory disease or allergic disease or mast cell disorders

Description

Inclusion Criteria:

• patients with a positive prick test or specific IgE regardless of the allergen
• patients suspected of allergic pathology defined by the need to carry out a prick test or specific IgE or a food or drug reintroduction test as part of the treatment
• patients with systemic or cutaneous mastocytosis according to the international classification8
• patients with mast cell activation syndrome according to the international classification8
• patients with familial hyper-alpha tryptasemia on the presence of variation in the number of copies of the alpha allele of the TPSAB1 gene
• patients with asthma of any severity
• people affiliated or beneficiaries of a social security scheme
• patients able to receive and understand the information on the study and their participation and having freely consented to it in writing before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and mastery of the French language).

Exclusion Criteria:

• patients under legal protection, guardianship or curatorship
• pregnant or breastfeeding women

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biobanking for Biomarkers In Respiratory Disease, Allergic diseases and/or mast cell disorders	constitution of a clinico-biological biobanking	15 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
set of diagnostic and/or prognostic biomarkers	identify new set of diagnostic and/or prognostic biomarkers	15 years
set of predictive biomarkers	Identify new biomarkers and/or a set of predictive biomarkers of the severity of the pathology or the response to treatments.	15 years
Allergy markers exploration	Explore if allergy markers (including asthma) or mastocytosis can be found in samples other than blood (urine, skin, etc.).	15 years
Estimation of concordance of biomarkers	Estimate the concordance of the presence of known and/or newly identified biomarkers of interest in the biological sample(s) making up the clinical-biological bank with the clinical data collected.	15 years
Evolution of biomarkers	Study the evolution over time of the biomarkers of interest and/or newly identified in the biological sample(s) constituting the clinical-biological bank.	15 years
Exploration of biological mechanisms	Explore through molecular and/or genomic and/or transcriptomic and/or proteomic studies the biological mechanisms specific to patients with allergic (including asthma) or mast cell pathologies to improve screening, diagnosis, orientation treatment and/or knowledge and understanding of these pathologies	15 years

Collaborators and Investigators

• Sponsor: University Hospital, Toulouse
• Investigators: Principal Investigator: Laurent GUILLEMINAULT, MD, University Hospital, Toulouse

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2024
• Primary Completion (Estimated): May 1, 2038
• Study Completion (Estimated): June 1, 2038

Study Registration Dates

• First Submitted: September 7, 2023
• First Submitted That Met QC Criteria: September 7, 2023
• First Posted (Actual): September 14, 2023

Study Record Updates

• Last Update Posted (Actual): May 1, 2024
• Last Update Submitted That Met QC Criteria: April 29, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: biomarkers; Allergy; asthma; biobank; mast cell disorders
• Additional Relevant MeSH Terms: Respiration Disorders; Respiratory Tract Diseases
• Other Study ID Numbers: RC31/23/0173

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No